TheyaVue blog
The TheyaVue Blog
Plain-language writing on eye supplements: what the AREDS trials tested and in whom, what a proprietary blend is allowed to leave out, and how a bottle and the page selling it end up saying different things. Six posts so far, and every one of them is useful if you never buy anything.
Written and reviewed by the TheyaVue Editorial Team · Last updated November 4, 2026
6 posts
All posts
November 6, 2026
TheyaVue Before and After: How to Record Your Own in 60 Days
No photos or trial results are published, so here is a simple way to write your own before and after inside the 60-day window.
Read it →November 6, 2026
TheyaVue Complaints: What Buyers Dislike and How to Raise One
A slow start, a 30-day bottle, price at checkout and phone-only refunds: each common complaint, with the fix.
Read it →November 6, 2026
TheyaVue on Amazon vs the Official Website
No marketplace is named as an authorised seller. What you keep on the official route, and five checks for any other listing.
Read it →October 30, 2026
TheyaVue Discount: Divide by Days Before You Trust One
No discount is published, and no price either. Here is how to compare any discount you meet by dividing the total by days.
Read it →October 30, 2026
TheyaVue Buy Capsules: How to Count, Swallow and Store Them
Sixty vegetable capsules a bottle: how to count the days, swallow them as directed and what the label does not say about storage.
Read it →October 30, 2026
TheyaVue Official: 5 Facts a Real Order Page Shows
Five facts any page claiming to be official should show: a seller, a phone line, a returns address, a 60-day window and a batch code.
Read it →August 31, 2026
What the AREDS2 Trial Actually Found
It is a real trial with real numbers. It is also not the trial most eye supplements imply it is.
Read it →September 12, 2026
When a Blend Hides the One Number That Matters
Ten ingredients, one total, and the two you came for sitting somewhere inside it.
Read it →September 21, 2026
When the Page Claims More Than the Bottle
The label is a regulated document. The headline above it is an advertisement. They are not required to agree, and often they do not.
Read it →About
What this blog is for
These posts exist because the questions people ask about TheyaVue are almost never really about TheyaVue. They are about the category. What did the trial everyone cites actually test, and in whom. What is a proprietary blend allowed to leave out, and why does it always seem to be the ingredient on the front of the bottle. And why does the label say one thing while the page selling it says something much larger. Those three questions arrive at the website team in one form or another most weeks, and none of them can be answered honestly in a sentence.
So each one got a post. Each post is written to be worth reading on its own terms, by somebody comparing two other products in a shop, who has never heard of this one and has no intention of buying it. Where TheyaVue appears, it appears as the worked example at the end — sometimes to its credit and sometimes not. Using somebody else’s product as the bad example while selling this one would be the cheapest move available, so this site does not make it.
Longer reference material sits in the guides section: a full guide to the eye-supplement category, and a step-by-step method for choosing within it. The blog is for the narrower questions that do not fit either.
The three
What is in each post
The six posts, and what each one is for
What the AREDS2 Trial Actually Found, published August 31, 2026, is about the National Eye Institute’s AREDS and AREDS2 trials, which are the most-cited research in this category and the most misquoted. The post prints both formulations exactly as NEI lists them, explains who was enrolled — people who already had intermediate or advanced age-related macular degeneration — and what slowing progression in that group does and does not mean for anyone else. It then prints the two sentences that almost never travel with the trial name in marketing: that the supplements do not prevent AMD onset, and that none of the formulations decreased cataract risk. It finishes on this bottle, where four ingredients overlap with the AREDS2 list and only copper matches at the directed dose.
When a Blend Hides the One Number That Matters, published September 12, 2026, is about the choice a manufacturer makes between declaring every amount and gathering several ingredients under one total. A proprietary blend is legal, common and usually harmless. It gives you exactly one usable fact: the names are listed heaviest first. The post works through this label in two halves, because it splits cleanly into them. Fifteen nutrients are declared individually with amounts and %DV, which is better disclosure than most of the category manages. Then 240.5 mg is shared by ten more ingredients, and two of those ten are lutein and zeaxanthin — the only figures AREDS2 gives this category to be judged on.
When the Page Claims More Than the Bottle, published September 21, 2026, is about the fact that a label and an advertisement are written to different rules. The post quotes the FDA’s own definitions of a structure/function claim and a disease claim, the disclaimer that is supposed to travel with the first kind, and the part that surprises most people: nobody pre-approves the wording. The worked example is this product, where the bottle says “Eye & Vision Support Formula” and carries the disclaimer, and the page the order button leads to is titled with a 20/20 eyesight claim. It ends with a thirty-second check you can run on any bottle you can pick up.
Method
How this blog works
How posts are chosen
By what the order line and the website team are actually asked, and by whether the answer is long enough to need a page. A question that can be answered in three sentences goes on the FAQ page instead. A question that needs a federal definition quoted, a table built, or a piece of arithmetic shown step by step becomes a post.
How posts are written
The same rules as the rest of this site. Every outside source is a government or national-body page, it is quoted rather than paraphrased, and the quotations are kept in one place in the generator so that no page can drift away from the wording. The sources for each post are listed at the end of it. No study identifier, author or date is printed from memory, and no trial of this formula is cited, because none was printed to us and none has been published.
No competitor is named anywhere, because a comparison written by a seller is an advertisement with a table in it. Where a number belongs to the seller rather than to a source we can check, it is labelled that way in the sentence that prints it. And on an eye product one message outranks everything else we can write, so it appears in all three posts: a dilated eye exam is the only way to catch many eye diseases early.
Corrections
Every post carries a published date and a last-updated date. If something here is wrong, write to [email protected] with the post and what is wrong; the post is corrected and its updated date moves forward. The website team answers Monday to Friday, 9:00am - 5:00pm ET, and it is not the sales line.
More posts
The generator behind this site reads posts from a list, so new ones can be added without touching any other page. The next ones queued are the two questions this label leaves open: what a standardisation figure would have told us about the bilberry, grape seed and eyebright inside the blend, and how to read a certificate of analysis if one is ever published against the batch codes the order line quotes.
Next